Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction

Rebecca Sullivan, Jinqiang Hou, Lihai Yu, Benjamin Wilk, Jane Sykes, Heather Biernaski, John Butler, Michael Kovacs, Justin Hicks, Jonathan D. Thiessen, Rohan Dharmakumar, Frank S. Prato, Gerald Wisenberg, Leonard G. Luyt, Savita Dhanvantari
{"title":"Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction","authors":"Rebecca Sullivan, Jinqiang Hou, Lihai Yu, Benjamin Wilk, Jane Sykes, Heather Biernaski, John Butler, Michael Kovacs, Justin Hicks, Jonathan D. Thiessen, Rohan Dharmakumar, Frank S. Prato, Gerald Wisenberg, Leonard G. Luyt, Savita Dhanvantari","doi":"10.2967/jnumed.124.267578","DOIUrl":null,"url":null,"abstract":"<p>The peptide hormone ghrelin is produced in cardiomyocytes and acts through the myocardial growth hormone secretagogue receptor (GHSR) to promote cardiomyocyte survival. Administration of ghrelin may have therapeutic effects on post–myocardial infarction (MI) outcomes. Therefore, there is a need to develop molecular imaging probes that can track the dynamics of GHSR in health and disease to better predict the effectiveness of ghrelin-based therapeutics. We designed a high-affinity GHSR ligand labeled with <sup>18</sup>F for imaging by PET and characterized its in vivo properties in a canine model of MI. <strong>Methods:</strong> We rationally designed and radiolabeled with <sup>18</sup>F a quinazolinone derivative ([<sup>18</sup>F]LCE470) with subnanomolar binding affinity to GHSR. We determined the sensitivity and in vivo and ex vivo specificity of [<sup>18</sup>F]LCE470 in a canine model of surgically induced MI using PET/MRI, which allowed for anatomic localization of tracer uptake and simultaneous determination of global cardiac function. Uptake of [<sup>18</sup>F]LCE470 was determined by time–activity curve and SUV analysis in 3 regions of the left ventricle—area of infarct, territory served by the left circumflex coronary artery, and remote myocardium—over a period of 1.5 y. Changes in cardiac perfusion were tracked by [<sup>13</sup>N]NH<sub>3</sub> PET. <strong>Results:</strong> The receptor binding affinity of LCE470 was measured at 0.33 nM, the highest known receptor binding affinity for a radiolabeled GHSR ligand. In vivo blocking studies in healthy hounds and ex vivo blocking studies in myocardial tissue showed the specificity of [<sup>18</sup>F]LCE470, and sensitivity was demonstrated by a positive correlation between tracer uptake and GHSR abundance. Post-MI changes in [<sup>18</sup>F]LCE470 uptake occurred independently of perfusion tracer distributions and changes in global cardiac function. We found that the regional distribution of [<sup>18</sup>F]LCE470 within the left ventricle diverged significantly within 1 d after MI and remained that way throughout the 1.5-y duration of the study. <strong>Conclusion:</strong> [<sup>18</sup>F]LCE470 is a high-affinity PET tracer that can detect changes in the regional distribution of myocardial GHSR after MI. In vivo PET molecular imaging of the global dynamics of GHSR may lead to improved GHSR-based therapeutics in the treatment of post-MI remodeling.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.124.267578","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The peptide hormone ghrelin is produced in cardiomyocytes and acts through the myocardial growth hormone secretagogue receptor (GHSR) to promote cardiomyocyte survival. Administration of ghrelin may have therapeutic effects on post–myocardial infarction (MI) outcomes. Therefore, there is a need to develop molecular imaging probes that can track the dynamics of GHSR in health and disease to better predict the effectiveness of ghrelin-based therapeutics. We designed a high-affinity GHSR ligand labeled with 18F for imaging by PET and characterized its in vivo properties in a canine model of MI. Methods: We rationally designed and radiolabeled with 18F a quinazolinone derivative ([18F]LCE470) with subnanomolar binding affinity to GHSR. We determined the sensitivity and in vivo and ex vivo specificity of [18F]LCE470 in a canine model of surgically induced MI using PET/MRI, which allowed for anatomic localization of tracer uptake and simultaneous determination of global cardiac function. Uptake of [18F]LCE470 was determined by time–activity curve and SUV analysis in 3 regions of the left ventricle—area of infarct, territory served by the left circumflex coronary artery, and remote myocardium—over a period of 1.5 y. Changes in cardiac perfusion were tracked by [13N]NH3 PET. Results: The receptor binding affinity of LCE470 was measured at 0.33 nM, the highest known receptor binding affinity for a radiolabeled GHSR ligand. In vivo blocking studies in healthy hounds and ex vivo blocking studies in myocardial tissue showed the specificity of [18F]LCE470, and sensitivity was demonstrated by a positive correlation between tracer uptake and GHSR abundance. Post-MI changes in [18F]LCE470 uptake occurred independently of perfusion tracer distributions and changes in global cardiac function. We found that the regional distribution of [18F]LCE470 within the left ventricle diverged significantly within 1 d after MI and remained that way throughout the 1.5-y duration of the study. Conclusion: [18F]LCE470 is a high-affinity PET tracer that can detect changes in the regional distribution of myocardial GHSR after MI. In vivo PET molecular imaging of the global dynamics of GHSR may lead to improved GHSR-based therapeutics in the treatment of post-MI remodeling.

心肌梗塞前后心肌生长激素分泌受体高亲和性 18F 标记放射性配体的设计、合成和临床前评估
多肽激素胃泌素产生于心肌细胞,并通过心肌生长激素分泌受体(GHSR)发挥作用,促进心肌细胞存活。施用胃泌素可能会对心肌梗死(MI)后的预后产生治疗效果。因此,有必要开发可跟踪 GHSR 在健康和疾病中动态变化的分子成像探针,以更好地预测以胃泌素为基础的疗法的效果。我们设计了一种用 18F 标记的高亲和力 GHSR 配体,用于 PET 成像,并在心肌梗死犬模型中鉴定了其体内特性。方法:我们合理地设计了一种喹唑啉酮衍生物([18F]LCE470),并用 18F 对其进行了放射性标记,该衍生物与 GHSR 的结合亲和力达到亚摩尔级。我们利用 PET/MRI 确定了[18F]LCE470 在手术诱导的心肌梗死犬模型中的灵敏度、体内和体外特异性,从而对示踪剂摄取进行了解剖定位,并同时确定了整体心脏功能。在 1.5 年的时间里,通过时间-活动曲线和 SUV 分析确定了左心室 3 个区域--梗死区、左冠状动脉周缘区域和远端心肌--对 [18F]LCE470 的摄取情况。通过[13N]NH3 PET 追踪心脏灌注的变化。结果:测得 LCE470 的受体结合亲和力为 0.33 nM,这是已知放射性标记 GHSR 配体的最高受体结合亲和力。健康猎犬体内阻断研究和心肌组织体外阻断研究显示了[18F]LCE470的特异性,而示踪剂摄取量与GHSR丰度之间的正相关则证明了其灵敏性。心肌梗死后[18F]LCE470摄取量的变化与灌注示踪剂分布和整体心脏功能的变化无关。我们发现,[18F]LCE470 在左心室内的区域分布在心肌梗死后 1 天内出现了明显的分化,并在 1.5 年的研究期间一直如此。结论[18F]LCE470是一种高亲和力PET示踪剂,可检测心肌梗死后心肌GHSR区域分布的变化。对 GHSR 的全球动态进行活体 PET 分子成像可能会改善基于 GHSR 的治疗方法,从而治疗心肌梗死后的重塑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信